Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases, starting with its lead candidate for myasthenia gravis. It last closed at $6.12 on Nov 17, up 0.66% on the day.
Only 1 firm rated RNAC in the past 90 days, not enough for a consensus
Average 12-month target
$40.00
▲ 553.6% upside
Based on 1 analyst who set a price target on RNAC in the past 90 days. The average target is $40.00, with a high of $40.00 and a low of $40.00, compared with the last close of $6.12.
Low $40.00Avg $40.00High $40.00
Blue marker: last close $6.12
Highest target$40.00
Average target$40.00
Lowest target$40.00
Latest rating changes
NeedhamReiterated
Sep 29Buy$40
BTIGReiterated
Jun 9Buy$44
NeedhamMaintained
May 26Buy$40
Date
Firm
Action
Rating
Price target
Sep 29
Needham
Reiterated
Buy
$40
Jun 9
BTIG
Reiterated
Buy
$44
May 26
Needham
Maintained
Buy
$40
Loading…
Technical Analysis
RNAC · as of the Nov 17 close · updated after every close
Downtrend
The stock is 7% below its 20 day and 15% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $6.07, and the nearest resistance the Pivot R1 at $6.22.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.4%/day
Key levels
$11.0052 week high+79.7%
$8.03100 day average+31.2%
$7.61200 day average+24.3%
$7.0250 day average+14.7%
$6.71Swing high (Oct 21)+9.6%
$6.5620 day average+7.2%
$6.22Pivot R1+1.6%
$6.12Last close
$6.07Pivot−0.8%
$6.07Swing low (Oct 26)−0.8%
$5.98Pivot S1−2.3%
$5.6052 week low−8.5%
Indicators
RSI (14)
39.40
Weak, oversold below 30
Neutral
MACD
-0.17
Below its signal line
Bearish
Stochastic
7.7
Near the bottom of its range
Oversold
ADX (14)
14.3
No clear trend
Williams %R
-90.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-127.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−4.5%
Change over 10 sessions
Bearish
ATR (14)
$0.45
Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 20.0%/day
Key levels
$11.0052 week high+79.7%
$8.03100 day average+31.2%
$7.61200 day average+24.3%
$7.0250 day average+14.7%
$6.71Swing high (Oct 21)+9.6%
$6.5620 day average+7.2%
$6.22Pivot R1+1.6%
$6.12Last close
$6.07Pivot−0.8%
$6.07Swing low (Oct 26)−0.8%
$5.98Pivot S1−2.3%
$5.6052 week low−8.5%
Indicators
RSI (14)
41.40
Middle of its range
Neutral
MACD
-0.47
Below its signal line
Bearish
Stochastic
14.0
Near the bottom of its range
Oversold
ADX (14)
12.7
No clear trend
Williams %R
-96.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-119.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.3%
Change over 10 sessions
Bearish
ATR (14)
$1.23
Typical daily range, 20.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNAC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RNAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RNAC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RNAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNAC is in one of them and how their past RNAC trades turned out.
Cartesian Therapeutics is a biotechnology company based in Frederick, Maryland, that is developing cell therapies for autoimmune diseases. Its approach uses mRNA to deliver a chimeric antigen receptor into a patient's own immune cells, which are then returned to the patient for outpatient treatment. Its lead product candidate, Descartes-08, is in clinical development for myasthenia gravis and certain myositis conditions. The company's target customers are patients with these conditions, and its products are not yet approved for sale.